Table 3. Patient outcomes at 26 weeks for adult native kidney patients, with application of stabilized weights.
| Outcomes | Eculizumab n = 39 |
Ravulizumab n = 46 |
p-value for the difference between groups (95% CI)a | |
|---|---|---|---|---|
| Dialysis | ||||
| Yes | n (%) | 3.1 (8) | 9.7 (22) | 0.070 (−1%, 30%) |
| 95% CI | 3%, 21% | 13%, 37% | ||
| No | n (%) | 35.9 (92) | 33.3 (78) | |
| 95% CI | 79%, 97% | 63%, 87% | ||
| Death | ||||
| Yes | n (%) | 0 (0) | 3 (7) | 0.103 (−1%, 14%) |
| 95% CI | 0%, 9% | 2%, 18% | ||
| No | n (%) | 39 (100) | 43 (93) | |
| 95% CI | 91%, 100% | 82%, 98% | ||
| eGFR category, mL/min/1.73m2 | ||||
| ≥ 90 | n (%) | 2.7 (7) | 12.3 (29) | |
| 95% CI | 2%, 19% | 17%, 44% | ||
| 60 – 89 | n (%) | 8 (20) | 8.7 (20) | |
| 95% CI | 11%, 35% | 11%, 35% | ||
| 45 – 59 | n (%) | 8.1 (21) | 1.9 (4) | |
| 95% CI | 11%, 36% | 1%, 15% | ||
| 30 – 44 | n (%) | 8.2 (21) | 4 (9) | |
| 95% CI | 11%, 36% | 4%, 22% | ||
| 15 – 29 | n (%) | 5.6 (14) | 3.6 (8) | |
| 95% CI | 7%, 29% | 3%, 20% | ||
| < 15 | n (%) | 3.9 (10) | 12.4 (29) | |
| 95% CI | 4%, 23% | 17%, 44% | ||
| SCr concentration in non-dialysis patients, mmol/L | ||||
| N | 36 | 33 | ||
| Mean (SD) | 152 (75) | 179 (281) | 0.595 (−73, 127) | |
| Platelet count, ×109/L | ||||
| N | 39 | 43 | ||
| Mean (SD) | 244 (65) | 243 (81) | 0.953 (−33, 31) | |
| LDH, U/L | ||||
| N | 39 | 43 | ||
| Mean (SD) | 179 (35) | 200 (60) | 0.059 (−1, 42) | |
| eGFR, mL/min/1.73m2 | ||||
| N | 39 | 43 | ||
| Mean (SD) | 51.4 (30.8) | 55.4 (40.8) | 0.619 (−12, 20) | |
| Systolic blood pressure, mmHg | ||||
| N | 39 | 43 | ||
| Mean (SD) | 131 (16) | 128 (19) | 0.449 (−11, 5) | |
| FACIT-F subscale score | ||||
| N | 30 | 40 | ||
| Mean (SD) | 40 (12) | 43 (9) | 0.382 (−3, 8) | |
| EQ-5D VAS | ||||
| N | 37 | 41 | ||
| Mean (SD) | 74 (20) | 79 (18) | 0.260 (−4, 13) | |
| EQ-5D TTO | ||||
| N | 37 | 41 | ||
| Mean (SD) | 0.89 (0.14) | 0.89 (0.15) | 0.890 (−0.06, 0.07) | |
aRepresents the 95% CI of the mean difference between treatments for continuous variables, and the 95% CI of the mean difference in proportions for categorical variables. For categorical variables, 95% CIs are presented only for binary outcomes and refer to the 95% CI around the difference between treatments for the first listed category (i.e., “Yes” for dialysis at endpoint). N is shown where patient data available differ from the overall number in each treatment group. Some values are given as decimal numbers owing to application of stabilized weights; n numbers represent outcome weights in each treatment group, the sum of which is the effective sample size. Percentages may not sum to 100% owing to rounding. CI = confidence interval; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; EQ-5D = 5-dimension EuroQol questionnaire; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; LDH = lactate dehydrogenase; SCr = serum creatinine; TTO = time trade-off; VAS = visual analog scale.